Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

25.45
+0.70002.83%
Pre-market: 26.941.49+5.85%04:59 EDT
Volume:296.73K
Turnover:7.49M
Market Cap:699.90M
PE:-9.47
High:25.77
Open:25.17
Low:24.78
Close:24.75
Loading ...

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

GlobeNewswire
·
11 Mar

Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen

TIPRANKS
·
11 Mar

Knight Therapeutics to Acquire Paladin Pharma for C$120M

Dow Jones
·
11 Mar

Press Release: DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

Dow Jones
·
11 Mar

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

GlobeNewswire
·
11 Mar

Ovid Therapeutics Q4 2024 GAAP EPS $(0.13) Beats $(0.16) Estimate, Sales $76K Miss $189.286K Estimate

Benzinga
·
11 Mar

Astria Therapeutics Q4 EPS $(0.44) Beats $(0.45) Estimate

Benzinga
·
11 Mar

Press Release: Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
11 Mar

Press Release: Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Dow Jones
·
11 Mar

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

GlobeNewswire
·
11 Mar

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

Business Wire
·
11 Mar

Xilio Therapeutics Q4 2024 GAAP EPS $(0.20) Beats $(0.21) Estimate, Xilio Anticipates That Its Cash And Cash Equivalents Of $55.3M As Of December 31, 2024, Together With The $52M Upfront Payments Received From AbbVie Is Expected To Provide Cash Runway Into Q1 Of 2026

Benzinga
·
11 Mar

Xilio Therapeutics reports Q4 EPS (20c) vs (64c) last year

TIPRANKS
·
11 Mar

Press Release: Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
11 Mar

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

GlobeNewswire
·
11 Mar

Werewolf Therapeutics Q4 2024 GAAP EPS $(0.46) Misses $(0.42) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Were $111M, Expected To Provide Cash Runway Into Q2 Of 2026

Benzinga
·
11 Mar